Element acquires Arch Sciences Group

Element Materials Technology has acquired Arch Sciences Group, a leading provider of analytical services and laboratory solutions in pharmaceuticals. As well as marking Element’s entry into the European pharmaceutical market, the move means that the life sciences end market is now the largest within Element.

Arch operates two divisions: the laboratory-based analytical services division, which directly supports drug development and new product regulatory approval cycles, and the technical laboratory solutions division, which supports a wide range of third-party laboratories.

The analytical services division, with laboratories in the UK and the US, provides a wide range of advanced analytical services with a global reputation for expertise in extractables and leachables testing services, and the testing of FDA-regulated consumer products.

The technical laboratory solutions division delivers technical services, training through its global market-leading online CHROMacademy platform, method development and support, and consumable products covering the supply of specialist third-party chromatography consumables. The technical laboratory solutions divisions also support the creation of automated laboratory systems and instruments to improve the accuracy, efficiency and effectiveness of chemical analysis; sample preparation; and liquid handling.

Jo Wetz, Element CEO, said: “Our acquisition of Arch complements our existing capabilities and expertise in the Americas after a period of significant growth there, and creates a strong platform to expand the pharmaceuticals segment of our life sciences business in Europe.”

Scott Fletcher, CEO at Arch, commented: “We are looking forward to joining Element’s global family and tapping into its expertise across a wide range of services and geographies. As Element pushes forward with expansion of its life sciences offering, it’s an exciting time to enter the business, and we’re thrilled to be able to offer our expert capabilities to grow Element’s presence in Europe, the US and hopefully beyond.”

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!

  • <<
  • >>

Join the Discussion